Kissei Pharmaceutical Co., Ltd.
KSPHF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $88,330,000 | $75,579,000 | $67,493,000 | $65,381,000 |
| % Growth | 16.9% | 12% | 3.2% | – |
| Cost of Goods Sold | $44,265,000 | $38,238,000 | $284,460 | $298,697 |
| Gross Profit | $44,065,000 | $37,341,000 | $223,559 | $238,408 |
| % Margin | 49.9% | 49.4% | 0.3% | 0.4% |
| R&D Expenses | $0 | $0 | $10,391,000 | $10,363,000 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $38,291,000 | $0 | $20,304,000 | $19,923,000 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1,000 | $33,324,000 | $2,809,000 | $2,354,000 |
| Operating Expenses | $38,292,000 | $33,324,000 | $33,504,000 | $32,640,000 |
| Operating Income | $5,773,000 | $4,017,000 | -$1,129,000 | -$1,402,000 |
| % Margin | 6.5% | 5.3% | -1.7% | -2.1% |
| Other Income/Exp. Net | $9,837,000 | $10,432,000 | $14,809,000 | $17,909,000 |
| Pre-Tax Income | $15,610,000 | $14,449,000 | $13,680,000 | $16,507,000 |
| Tax Expense | $3,634,000 | $3,159,000 | $3,046,000 | $3,475,000 |
| Net Income | $11,961,000 | $11,160,000 | $10,528,000 | $12,921,000 |
| % Margin | 13.5% | 14.8% | 15.6% | 19.8% |
| EPS | 274.21 | 246.58 | 228.31 | 280.2 |
| % Growth | 11.2% | 8% | -18.5% | – |
| EPS Diluted | 274.21 | 246.58 | 228.31 | 280.2 |
| Weighted Avg Shares Out | 43,620 | 45,258 | 46,115 | 46,115 |
| Weighted Avg Shares Out Dil | 43,620 | 45,258 | 46,115 | 46,115 |
| Supplemental Information | – | – | – | – |
| Interest Income | $57,000 | $21,000 | $23,000 | $42,000 |
| Interest Expense | $21,000 | $18,000 | $20,000 | $23,000 |
| Depreciation & Amortization | $4,615,000 | $4,254,000 | $4,109,000 | $3,730,000 |
| EBITDA | $20,246,000 | $18,721,000 | $2,966,000 | $2,328,000 |
| % Margin | 22.9% | 24.8% | 4.4% | 3.6% |